Eli Lilly has announced the sale of its manufacturing facility in Branchburg, New Jersey, signaling a strategic redirection away from monoclonal antibody production toward advanced biologics. The divestiture aligns with evolving pharmaceutical market demands favoring complex biologics. Lilly is actively pursuing new U.S.-based manufacturing sites to bolster its biologic portfolio, thereby optimizing operational efficiency and maintaining competitiveness amid rapid industry innovation.